Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Safety and Effect of Different Doses of TENDU Vaccine, a Therapeutic Peptide Conjugate Vaccine, in Patients With Relapse After Primary Radical Prostatectomy

Next Previous
X
Search
Trial Profile

Safety and Effect of Different Doses of TENDU Vaccine, a Therapeutic Peptide Conjugate Vaccine, in Patients With Relapse After Primary Radical Prostatectomy

Status: Completed
Phase of Trial: Phase I

Latest Information Update: 17 Jul 2024

Price :

$35 *

Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs UV 2 (Primary)
  • Indications Prostate cancer
  • Focus Adverse reactions; First in man
  • Acronyms TENDU
  • Sponsors Ultimovacs AS

    • Most Recent Events

    • 10 Apr 2024 Results presented at the 115th Annual Meeting of the American Association for Cancer Research
    • 04 Apr 2024 According to an Ultimovacs ASA media release, data from the study will be presented in a poster at the 2024 American Association for Cancer Research (AACR), taking place April 5-10, 2024, in San Diego, CA.
    • 14 Feb 2024 According to an Ultimovacs ASA media release, this study based on TET technology met the primary endpoint.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top